nafamostat has been researched along with Autoimmune Diseases in 3 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Autoimmune Diseases: Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iyer, A | 1 |
| Xu, W | 1 |
| Reid, RC | 1 |
| Fairlie, DP | 1 |
| Ogawa, M | 1 |
| Mori, Y | 1 |
| Ueda, S | 1 |
| Mori, T | 1 |
| Makino, Y | 1 |
| Hori, J | 1 |
| Ohto, M | 1 |
| Wakashin, M | 1 |
| Ikehara, S | 1 |
| Shimamura, K | 1 |
| Aoyama, T | 1 |
| Fujii, S | 1 |
| Hamashima, Y | 1 |
1 review available for nafamostat and Autoimmune Diseases
| Article | Year |
|---|---|
Chemical Approaches to Modulating Complement-Mediated Diseases.
Topics: Animals; Autoimmune Diseases; Cell Line, Tumor; Complement Activation; Complement Inactivating Agent | 2018 |
2 other studies available for nafamostat and Autoimmune Diseases
| Article | Year |
|---|---|
Protective effects of FUT-175 on acute massive hepatic necrosis induced in mice following endotoxin injection and immunization with liver proteins.
Topics: Acute Disease; Animals; Autoimmune Diseases; Benzamidines; Chemical and Drug Induced Liver Injury; E | 1993 |
Effect of FUT-175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB x NZW) F1 mice.
Topics: Animals; Autoimmune Diseases; Benzamidines; Female; Glomerulonephritis; Guanidines; Lupus Erythemato | 1985 |